tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2021 Jul 10;99:107970.
doi: 10.1016/j.intimp.2021.107970. Online ahead of print.
Autoimmune phenomena following SARS-CoV-2 vaccination
Yuval Ishay[SUP] 1 [/SUP], Ariel Kenig[SUP] 2 [/SUP], Tehila Tsemach-Toren[SUP] 3 [/SUP], Radgonde Amer[SUP] 4 [/SUP], Limor Rubin[SUP] 5 [/SUP], Yoav Hershkovitz[SUP] 2 [/SUP], Fadi Kharouf[SUP] 6 [/SUP]
Affiliations
Abstract
Vaccines represent an attractive possible solution to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Widespread vaccine distribution has yet to occur in most countries, partially due to public concerns regarding possible side effects. While studies indicate the vaccine is exceptionally safe, rare systemic side effects remain possible. In Israel, where a large percentage of the population has been rapidly vaccinated, such adverse events may be more apparent. We report a series of patients presenting with de-novo or flares of existing autoimmune conditions associated with the Pfizer BNT162b2 mRNA SARS-CoV-2 vaccine. All patients were assessed in our tertiary care center in Israel and had no history of previous SARS-COV-2 infection. We observed that while immune phenomena may occur following vaccination, they usually follow a mild course and require modest therapy. We briefly expound on the theoretical background of vaccine related autoimmunity and explore future research prospects.
Keywords: Autoimmunity; BNT162b2; COVID-19; SARS-CoV-2; Vaccines.
. 2021 Jul 10;99:107970.
doi: 10.1016/j.intimp.2021.107970. Online ahead of print.
Autoimmune phenomena following SARS-CoV-2 vaccination
Yuval Ishay[SUP] 1 [/SUP], Ariel Kenig[SUP] 2 [/SUP], Tehila Tsemach-Toren[SUP] 3 [/SUP], Radgonde Amer[SUP] 4 [/SUP], Limor Rubin[SUP] 5 [/SUP], Yoav Hershkovitz[SUP] 2 [/SUP], Fadi Kharouf[SUP] 6 [/SUP]
Affiliations
- PMID: 34280851
- DOI: 10.1016/j.intimp.2021.107970
Abstract
Vaccines represent an attractive possible solution to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Widespread vaccine distribution has yet to occur in most countries, partially due to public concerns regarding possible side effects. While studies indicate the vaccine is exceptionally safe, rare systemic side effects remain possible. In Israel, where a large percentage of the population has been rapidly vaccinated, such adverse events may be more apparent. We report a series of patients presenting with de-novo or flares of existing autoimmune conditions associated with the Pfizer BNT162b2 mRNA SARS-CoV-2 vaccine. All patients were assessed in our tertiary care center in Israel and had no history of previous SARS-COV-2 infection. We observed that while immune phenomena may occur following vaccination, they usually follow a mild course and require modest therapy. We briefly expound on the theoretical background of vaccine related autoimmunity and explore future research prospects.
Keywords: Autoimmunity; BNT162b2; COVID-19; SARS-CoV-2; Vaccines.